Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David Anthony Lowe is active.

Publication


Featured researches published by David Anthony Lowe.


Biotechnology Letters | 1986

Enzymatic hydrolysis of penicillin V to 6-aminopenicillanic acid byFusariumoxysporum

David Anthony Lowe; Guna Romancik; Richard Paul Elander

SummaryA strain ofFusariumoxysporum was identified as having an intracellular penicillin V acylase activity (penicillin V amidohydrolase EC 3.5.1.11). Activity was induced by phenoxyacetic acid and had a good tolerance for high substrate and product concentrations. Washed cells could be used repeatedly for the complete hydrolysis of 5% penicillin V solutions. The enzyme was partially purified and concentrated from disrupted cells by fractional precipitation with water miscible solvents.


Drug Delivery | 1995

Sulfated etoposide and nitrogen mustard prodrugs and their activation by streptomyces arylsulfatase

Peter D. Senter; Philip M. Wallace; John E. Somerville; Ing-Kae Wang; David Anthony Lowe

AbstractEtoposide sulfate (ES) and p-di-2-chloroethylaminophenyl sulfate (CAPS) were designed as nontoxic anticancer prodrugs of etoposide and p-di-2-chloroethylaminophenol (CAP) that could be activated on tumor cell surfaces by monoclonal antibody (mAb)-arylsulfatase conjugates. In vitro assays indicated that CAPS and ES were nontoxic to the H2981 human lung adenocarcinoma cell line, while etoposide and CAP had IC50 values of 1–2 μM. Several commercially available arylsulfatases, as well as the arylsulfatases from human liver and urine, were either unable or poorly able to effect the hydrolysis of ES and CAPS. In contrast, arylsulfatase from Streptomyces (SAS) hydrolyzed ES and CAPS with specific activities of 3.0 and 4.8 μmol/min/ mg, respectively. SAS was conjugated to the L6 mono-clonal antibody and was able to activate ES in an immunologically specific manner on H2981 cells (L6 antigen positive). ES and CAPS were stable in mouse serum and were at least 9–13 times less toxic to mice on a molar basis t...


Archive | 1995

Enzymatic acylation of 3-hydroxymethyl cephalosporins

John J. Usher; Guna Romancik; Michael Politino; David Anthony Lowe


Archive | 2002

D-hydantoinase from Ochrobactrum anthropi

Michael Politino; Sean M. Tonzi; Guna Romancik; John J. Usher; David Anthony Lowe


Archive | 1984

Production of cephalosporin C

David Anthony Lowe; Guna Romancik; Leonardo M. Cappelletti; Richard Paul Elander


Archive | 2002

D-hydantoinase aus ochrobactrum anthropi D-hydantoinase from Ochrobactrum anthropi

Michael Politino; Sean M. Tonzi; Guna Romancik; John J. Usher; David Anthony Lowe


Archive | 2002

D-hydantoinase issus d'ochrobactrum anthropi

David Anthony Lowe; Michael Politino; Guna Romancik; Sean M. Tonzi; John J. Usher


Archive | 1984

Procedure for the preparation of cephalosporin C

David Anthony Lowe; Guna Romancik; Leonardo M. Cappelletti; Richard Paul Elander


Archive | 1984

A process for the production of cephalosporin C

David Anthony Lowe; Guna Romancik; Leonardo M. Cappelletti; Richard Paul Elander


Archive | 1984

A process for the preparation of cephalosporin C and the use of specified phosphorus compounds for reducing the formation of desacetylcephalosporin C by culturing a cephalosporin C-producing microorganism which also produces desacetylcephalosporin C.

David Anthony Lowe; Guna Romancik; Leonardo M. Cappelletti; Richard Paul Elander

Collaboration


Dive into the David Anthony Lowe's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge